IMMUTEP LIMITED - Corporate Spotlight

Market Cap $486.6M Add to my watchlist

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

No Corporate Spotlight currently available.

(20min delay)
Last 32.5¢		Change 0.005(1.56%)		Mkt cap ! $486.6M

Open	High	Low	Value	Volume
31.0¢	32.5¢	31.0¢	$443.3K	1.392M

Buyers (Bids)

No.	Vol.	Price($)
1	15000	32.0¢

Sellers (Offers)

Price($)	Vol.	No.
32.5¢	462081	5

View Market Depth

No.	Vol.	Price($)
4	115519	0.395
3	76000	0.390
4	68064	0.385
10	225656	0.380
1	8500	0.375

Price($)	Vol.	No.
0.405	37481	2
0.410	240538	10
0.415	229395	10
0.420	502644	9
0.425	50700	3

Last trade - 16.10pm 03/12/2024 (20 minute delay)


Last 32.5¢		Change 0.005 ( 0.43 %)
Open	High	Low	Volume
31.5¢	32.5¢	31.5¢	735148
Last updated 15.59pm 03/12/2024 ?

IMM (ASX) Chart